Sage Journals: Discover world-class research

Abstract

Objectives

The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing–remitting multiple sclerosis (RRMS).

Methods

Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GM^V) and white matter (WM^V) volumes.

Results

The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy.

Conclusions

Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.

Keywords

anti-GM1 relapsing–remitting multiple sclerosis

Get full access to this article

View all access options for this article.

References

1 Acarìn N Rìo J Fernàndez AL . Different antiganglioside antibodies pattern between relapsing remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99–103.

2 Sadatipour BT Greer JM Pender MP . Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980–983.

3 Tedeschi G Lavorgna L Russo P . Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280–285.

4 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

5 Zappia M Crescibene L Bosco D . Anti-GM1 ganglioside antibodies in Parkinson’s disease. Acta Neurol Scand 2002; 106: 54–57.

6 Smith SM Zhang Y Jenkinson M . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.

7 Giovannoni G Morris PR Keir G . Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann Neurol 2000; 47: 684–685.

Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis

Abstract

Keywords

Get full access to this article

References